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ABSTRACT 
Background: Health-related quality of life (HRQoL) from diagnosis until end of treatment for children 
with Acute Lymphoblastic Leukaemia (ALL) was investigated, examining effects of age, gender, risk 
ƐƚƌĂƚŝĨŝĞĚƚƌĞĂƚŵĞŶƚƌĞŐŝŵĞŶ ? ? ? ?ĂŶĚƚŚĞƌĂƉǇŝŶƚĞŶƐŝƚǇ ? ?ǀƐ ? ‘ĚĞůĂǇĞĚŝŶƚĞŶƐŝĨŝĐĂƚŝŽŶƐ ? P/ ? ? 
Method 
In a multi-ĐĞŶƚƌĞƉƌŽƐƉĞĐƚŝǀĞƐƚƵĚǇ ?ƉĂƌĞŶƚƐƌĞƉŽƌƚĞĚƚŚĞŝƌĐŚŝůĚ ?ƐŐĞŶĞƌŝĐĂŶĚĚŝƐĞĂse specific 
HRQoL and their own care-giving burden at five time-points. From 1428 eligible patients, 874 
parents completed questionnaires at least once during treatment.  
Results 
At each time-point, generic HRQoL was significantly lower than equivalent norm scores for healthy 
children. HRQoL decreased significantly at the start of treatment, before recovering gradually (but 
remained below pre-treatment levels). Parents reported that older children worried more about side 
effects and their appearance but showed less procedural anxiety than younger children. Concern for 
appearance was greater among girls than boys. Compared to regimen B (i.e.additional doxorubicin 
during induction and additional cyclophosphamide and cytarabine during consolidation 
chemotherapy), patients receiving regimen A had fewer problems with pain and nausea. There were 
no statistically significant differences in HRQoL by number of DI blocks received. 
Interpretation: HRQoL is compromised at all stages of treatment, and is partly dependent on age. 
dŚĞĨŝŶĚŝŶŐƐŝŶĐƌĞĂƐĞƵŶĚĞƌƐƚĂŶĚŝŶŐŽĨƚŚĞŝŵƉĂĐƚŽĨƚŚĞƌĂƉǇŽŶĐŚŝůĚƌĞŶ ?Ɛ,ZYŽ>ĂŶĚƉĂƌĞŶƚĂůĐĂƌĞ-
giving burden, and will contribute to the design of future trials. 
  
Keywords: paediatric oncology, quality of life, acute leukaemia 
. 
  
  
  
BACKGROUND 
Acute lymphoblastic leukaemia (ALL) is the commonest childhood malignancy, affecting 
approximately 400 children in the UK annually. Over 80% now achieve long-term cure. Stratification 
by cytogenetics ĂŶĚDŝŶŝŵĂůZĞƐŝĚƵĂůŝƐĞĂƐĞ ?DZ ?ŝĚĞŶƚŝĨŝĞƐĂ ‘ůŽǁƌŝƐŬ ? ƵďŐƌŽƵƉŽĨƉĂƚŝĞŶƚƐ ? ? ? ?
with an excellent chance of cure, (>90% 5-year event free survival). Those with persistent MRD at 
ƚŚĞĞŶĚŽĨŝŶĚƵĐƚŝŽŶ ? ‘ŚŝŐŚƌŝƐŬ ? ?ŚĂǀĞĂŐƌĞĂƚĞƌƌŝƐŬŽĨĞĂƌůǇƌĞůĂƉƐĞ ? 
  
UKALL 2003 was a randomised clinical trial testing whether the efficacy and toxicity of treatment for 
children and young adults with ALL could be optimised through MRD stratification.  Following 
induction, sub-groups at low or high risk of relapse predicted by MRD were randomised to treatment 
ƌĞĚƵĐƚŝŽŶŽƌŝŶƚĞŶƐŝĨŝĐĂƚŝŽŶƌĞƐƉĞĐƚŝǀĞůǇ ?dŚŽƐĞĐůĂƐƐŝĨĞĚĂƐ ‘DZůŽǁ-ƌŝƐŬ ? ?ƵŶĚĞƚĞĐƚĂďůĞDZĂƚ
induction day 29 or detectable <0.001% leukaemic cells at day 29 becoming undetectable by week 
11) were randomly assŝŐŶĞĚƚŽŽŶĞ ?ĞǆƉĞƌŝŵĞŶƚĂůĂƌŵ ?ŽƌƚǁŽ ?ƐƚĂŶĚĂƌĚƚŚĞƌĂƉǇ ?ďůŽĐŬƐŽĨ ‘ĚĞůĂǇĞĚ
ŝŶƚĞŶƐŝĨŝĐĂƚŝŽŶ ? ?/ ?ĐŚĞŵŽƚŚĞƌĂƉǇƉƌŝŽƌƚŽŵĂŝŶƚĞŶĂŶĐĞ ?dŚŝƐ ĂĚĚŝƚŝŽŶĂůĐŚĞŵŽƚŚĞƌĂƉǇĐŽŵƉƌŝƐĞĚ
doxorubicin, etoposide, cyclophosphamide over a 5-day period followed by a period of neutropenia, 
ǁŝƚŚďůŽŽĚĐŽƵŶƚƌĞĐŽǀĞƌǇďǇĚĂǇ ? ? ?WĂƚŝĞŶƚƐǁŝƚŚDZA? ? ? A?WƵďDĞĚĂƚƚŚĞĞŶĚŽĨŝŶĚƵĐƚŝŽŶ
ǁĞƌĞĐůĂƐƐŝĨŝĞĚĂƐ ‘DZŚŝŐŚƌŝƐŬ ?ĂŶĚǁĞƌĞƌĂŶĚŽŵŝƐĞĚƚŽĐŽŶƚŝŶƵĞƐƚĂŶĚĂƌĚƚŚĞƌĂƉǇ ?ZĞŐŝŵĞŶŽƌ
B) or to intensify treatment further (Regimen C). There was an improvement in 5-year event-free 
survival to 87% in the trial overall, with no increase in relapse risk associated with de-escalation of 
treatment in the low risk group [2] and a reduction in relapse risk in high risk patients who received 
more intensive treatment [3]. 
  
These excellent survival outcomes raise questions about how to balance treatment-related 
morbidity and health-related quality of life (HRQoL). Physical side effects of chemotherapy [4], 
repeated hospitalisations, and associated limitations for social and physical opportunities [5], all 
ĐŽŵƉƌŽŵŝƐĞĂĐŚŝůĚ ?Ɛ,ZYŽ> ? 
  
When assessing HRQoL, a distinction is made between generic and disease-specific measures [6]. 
Generic measures enable comparison with the general population, while disease-specific measures 
focus on disease symptoms, and are considered more sensitive to evaluate different treatments. 
Although ratings of child HRQoL should be made by both child and parent [7], it is often necessary to 
ƌĞůǇŽŶƉĂƌĞŶƚƐ ?ƉƌŽǆǇƌĂƚŝŶŐƐ ? especially where children are too young or ill to respond themselves. 
Parents are under intense stress given the emotional and financial costs of caring for a sick child [8]. 
Family care-giving burden therefore needs to be considered as an integral part of any 
comprehensive evaluation of HRQoL. 
  
The aim of this study was to assess HRQoL of children treated in the UKALL 2003 trial from diagnosis 
until end of treatment. Parent proxy and patient reports (from children aged > 8 years) were 
collected. Specifically, the following were determined i) generic HRQoL compared with population 
norms; ii) changes in generic and disease-specific HRQoL over time, depending on child age, gender 
and treatment regimen; iii) differences in HRQoL between low-risk patients randomised to 
treatment reduction and those receiving standard care; iv) differences in HRQoL between high-risk 
patients randomised to treatment intensification and those receiving standard care. 
  
  
METHODS 
  
From October 1st 2003 until June 30th 2011, children and young adults aged 1-25 years with ALL 
(original age-limit was 18 years, extended to 20 years in February 2006, and 25 years in August 2007) 
were recruited from 45 centres across the UK and Ireland (2), with 3126 patients eligible for the 
main trial (ISRCTN 07355119). Inclusion criteria for the HRQoL study were that: i) children were 
registered on UKALL 2003, and aged between 4 -18 years; ii) a parent was able to complete 
questionnaires in English; and iii) parents (or patients over 16 years) gave signed informed consent.  
Recruitment to the HRQoL study ceased ahead of the main trial on October 26th 2009. Ethical 
approval was granted by the Scottish Multicentre Research Ethics Committee. Clinic staff 
approached parents of eligible patients in clinic, gave written information and obtained signed 
consent for participation. 
  
UKALL2003 treatment summary 
Patients recruited to UKALL 2003 were initially stratified by clinical risk of relapse. Chemotherapy 
regimens A (Standard) B (Intermediate) and C (high risk) were defined by National Cancer Institute 
(NCI) criteria, cytogenetics, and morphological early response to treatment [2]. Standard and 
intermediate risk patients were assessed for MRD and randomised on the basis of MRD status at day 
29 as described above. All patients received induction chemotherapy with vincristine, 
dexamethasone, asparaginase and intrathecal methotrexate.  Patientson regimen B received 
additional doxorubicin during induction (weeks 1-4) and additional cyclophosphamide and 
cytarabine during consolidation chemotherapy (weeks 7-15). Regimen C comprised two additional 
cycles of Capizzi maintenance (asparaginase and escalating doses of methotrexate) during weeks 15-
22 and 31-38.   Only patients receiving Regimens A and B were randomised between one versus two 
blocks of DI as noted above.  All patients in regimen C received two DI blocks of chemotherapy.  
Following the second DI all patients commenced maintenance chemotherapy comprising daily 6-
mercaptopurine, weekly oral methotrexate and 4 weekly pulses of vincristine with 5 days of 
dexamethasone.  Maintenance chemotherapy continued for 2 years in girls and 3 years in boys [2]. 
  
HRQoL study 
Questionnaires were completed at five time-points (T1-T5), during scheduled clinic appointments. 
T1: as soon as possible after diagnosis, with parents asked to provide a baseline assessment of their 
ĐŚŝůĚ ?Ɛ,ZYŽ>ďĞĨŽƌĞĚŝĂŐŶŽƐŝƐ ?ĂŶĚĐĂƌĞ-giving burden immediately after diagnosis); T2: (week 4) 
end of induction chemotherapy; T3: immediately prior to maintenance therapy, (week 23 for 
patients who received regimen A & one DI to week 47 for those who received Regimen C); T4: 
completed at 18 months (during maintenance chemotherapy); T5: end of therapy. 
  
  
Measures and assessment strategy 
  
ŚŝůĚ ?Ɛ,ZYŽ> P 
The PedsQL4.0 generic core [9] is a 23-item scale that yields three scores for each time-point (Total, 
Physical and Psychosocial HRQoL) [10]. Five-ƉŽŝŶƚƌĞƐƉŽŶƐĞƐĐĂůĞƐ ? ? ?A? ‘ŶĞǀĞƌĂƉƌŽďůĞŵ ?ƚŽ ?A?
 ‘ĂůŵŽƐƚĂůǁĂǇƐĂƉƌŽďůĞŵ ? ?ǁĞƌĞƵƐĞĚĨŽƌĞĂĐŚŝƚĞŵ ?/ƚĞŵƐĂre reverse-scored (and linearly 
transformed to a 0-100 scale) with higher scores indicating better HRQoL.  
  
The PedsQL 3.0 Cancer Module [11] is a 27-item questionnaire comprising eight subscales to assess 
the impact of disease and treatment on pain and hurt, nausea, procedural anxiety, treatment 
anxiety, worry about side-effects, cognitive problems, concern for appearance and communication. 
In order to ensure relevance to a UK sample, the Anglicised version of PedsQL which has been 
confirmed to be both valid and reliable in the UK population [12] was used. Questions which were 
also present in the PedsQL generic version were removed from the cancer module in order to reduce 
the overall length of the questionnaire. This resulted in a 19-item scale assessing pain and hurt, 
nausea, procedural anxiety, worry about side-effects, concern for appearance and communication. 
Five-ƉŽŝŶƚƌĞƐƉŽŶƐĞƐĐĂůĞƐ ? ? ?A? ‘ŶĞǀĞƌĂƉƌŽďůĞŵ ?ƚŽ ?A? ‘ĂůŵŽƐƚĂůǁĂǇƐĂƉƌŽďůĞŵ ? ?ǁĞƌĞƵƐĞĚ ?ǁŝƚŚ
higher scores representing worse outcomes. 
  
Parental caregiving burden 
ŵŽĚŝĨŝĞĚŵĞĂƐƵƌĞŽĨƉĂƌĞŶƚƐ ?ƉĞƌĐĞŝǀĞĚĐĂƌĞ-giving burden in families with a child with asthma 
was used [13]. The resulting scale comprised 11 items asking parents how often they were bothered 
about specific tasks associated wŝƚŚƚŚĞŝƌĐŚŝůĚ ?ƐŝůůŶĞƐƐ ?ZĞƐƉŽŶƐĞƐǁĞƌĞŵĂĚĞŽŶ ?-point Likert 
ƐĐĂůĞƐ ? ? ?A? ?ĂůůŽĨƚŚĞƚŝŵĞ ?ƚŽ ?A? ‘ŶŽŶĞŽĨƚŚĞƚŝŵĞ ? ? ?^ĐŽƌĞƐǁĞƌĞƌĞǀĞƌƐĞĚƐŽƚŚĂƚŚŝŐŚĞƌƐĐŽƌĞƐ
indicated greater care-giving burden. 
  
Questionnaires were distributed in paper version to the treatment centres and given to patients by 
the leukaemia specialist nurses or data management team. Completed questionnaires were sent 
back to the UKALL 2003 Clinical Trials Centre (Sheffield, UK) and data entered by the trials data 
manager . The reĐĂůůƉĞƌŝŽĚĂƐĚĞƐĐƌŝďĞĚŝŶƚŚĞƋƵĞƐƚŝŽŶŶĂŝƌĞǁĂƐ “ŽǀĞƌƚŚĞůĂƐƚ ?ǁĞĞŬƐ ? ?WĂƌĞŶƚƐ
answered the same questionnaires at all five time-points, except that the Cancer Module was not 
administered at T1 since items were not relevant before treatment began. (See web appendix for 
individual items). 
  
Statistical analysis 
Responses were checked for temporal consistency (that response date fell close to scheduled time-
point(allowing for treatment schedules at T3, and gender at T5). Responses between 2 weeks before 
and 6 weeks after scheduled T1 or T2, and between 3 months before and 20 weeks after scheduled 
T3, T4 or T5 were considered acceptable. Responses outside these ranges were excluded as were 
those completed after relapse or stem cell transplant. These relatively large ranges were necessary 
given travel times to hospitals and differences in duration between treatment regimens. 
HRQoL, demographics and treatment regimens grouped by response pattern over time were 
measured in order to compare non-responders with responders and detect bias related to non-
response. Phi correlations and chi-square tests were used to determine relationships between non-
response at one or more time-points and gender, age, initial white blood count or treatment 
regimen. One-sample t-tests were used to compare mean Total, Physical and Psychosocial HRQoL at 
each time-point against population norms [10]. 
  
A multilevel growth model for longitudinal data [14] was used to determine level, change over time, 
and variation in change over time, for each outcome variable (i.e. generic HRQoL: Total, Physical and 
Psychosocial subscales; six cancer-specific HRQoL subscales; and care-giving burden) and the extent 
to which any variation was explained by age, gender and treatment. Multilevel modelling was 
considered preferable to repeated measures ANOVA, since it enabled use of data from those who 
did not respond at every time-point, and offered flexibility in modelling intra-subject correlation (i.e. 
non-independence of observations) across time.  
  
The modelling process comprised three stages for each outcome variable. First, the shape of change 
over time was determined by introducing response time-ƉŽŝŶƚĂƐĂƉƌĞĚŝĐƚŽƌ ? ‘ƵŶĐŽŶĚŝƚŝŽŶĂůůŝŶĞĂƌ
ŐƌŽǁƚŚŵŽĚĞů ? ? ?ZĞƐƉŽŶƐĞƚŝŵĞ-point was treated as a factor due to varying temporal distance 
between time-points and the possible non-linear pattern of change over the study period. The 
chosen dummy coding of time contrasted each time-point against the preceding time-point (i.e. 
 ‘ƌĞƉĞĂƚĞĚĐŽŶƚƌĂƐƚƐ ? ? ?^ĞĐŽŶĚ ?ǀĂƌŝĂďůĞs were added as predictors of HRQoL to determine main 
effects of age at registration (continuous variable), gender (male vs. female) and treatment (regimen 
received: A, B or C; number of DIs received: 1 vs 2 and, where relevant, randomised allocation: low 
risk 1 vs 2 DIs, high risk regimen A/B vs C). Lastly, the 2-way interaction effects of each of these 
variables with time-point were added to determine whether change in HRQoL over time varied by 
age, gender, treatment regimen or number of DIs. Analyses of treatment regimen received allowed 
for age and sex differences in regimens. Analyses of the effect of randomised allocation on HRQoL 
were restricted to T3 to T5 as randomisation took place at T2. Similarly, analyses of the effect of DIs 
on HRQoL were restricted to T3 to T5. 
  
For each model an autoregressive (AR1) correlation structure was fitted to within subject variance to 
account for non-independence of questionnaires over time. Correlations detected between adjacent 
time-points were all positive and non-trivial across different outcome measures, (range 0.12 < rho < 
0.28), indicating efficacy of modelling within-ƐƵďũĞĐƚ ‘ŶƵŝƐĂŶĐĞ ?ǀĂƌŝĂƚŝŽŶ ? 
  
Analyses were conducted using SPSS v21.0 and SAS v9.3 software. Unstandardised regression 
coefficients (B) and significance levels of p < 0.05, p < 0.005 and p < 0.0005 are reported throughout. 
We used Bonferroni-corrected p-values and confidence intervals when assessing statistical 
significance. 
  
RESULTS 
  
Internal consistency reliabilities for PedsQL were acceptable at each time-point (Physical: 0.89 < 
alpha, T1-T5 < 0.93; Psychosocial: 0.79 < alpha, T1-T5 < 0.89) and for the cancer module (Pain and 
hurt: 0.77 < alpha, T2-T5 < 0.86; nausea: 0.79 < alpha, T2-T5 < 0.85; procedural anxiety: 0.88 < alpha, 
T2-T5 < 0.90; worry about side effects: 0.87 < alpha, T2-T5 < 0.89; concern for appearance: 0.79 < 
alpha, T2-T5 < 0.84; communication 0.87 < alpha, T2-T5 < 0.90). For the Parental Caregiving Burden 
ƐĐĂůĞ ?ŽŶĞŝƚĞŵ ? ‘ǁŽƌƌŝĞĚǁŚĞƚŚĞƌŽƌŶŽƚƚŽƌŝŶŐƚŚĞŚŽƐƉŝƚĂů ? ?ǁĂƐƌĞmoved after reliability analysis, 
leaving a 10-item scale with satisfactory internal consistency reliability at each time-point (0.87 < 
alpha, T1-T5 < 0.92). 
Of 1428 eligible patients, 904 (63%) were enrolled, i.e. child or parent responded at least once 
(Figure 1), but 11 cases included only child responses, giving 893 parents who responded at least 
once. After excluding questionnaires completed post-transplant, post-relapse or outside the 
acceptable response time frame (4-8% at each time-point), there were 2567 eligible questionnaires, 
from parents of 874 patients, across time-points (T1, N = 681; T2, N = 601; T3, N = 526; T4, N = 448; 
T5, N = 311). Parents completed a median of 3 eligible questionnaires, 152 responded at all 5 time-
points. Table 1 outlines the number of responses received and the number of eligible participants at 
each time point. 
  
Among eligible patients (N = 1428), there were no demographic or clinical differences between the 
analysis sample (n = 874), and non-responders (including those who returned invalid questionnaires, 
n = 554), p>0.1 in each case. The groups had similar demographic profiles (responders: 55% male, 
median age at registration = 8 years, median white blood cell count 10x109/L; non-responders: 59% 
male, median age at registration = 8 years, median white cell count 11x109/L)and treatment 
regimens (responders: 41% received regimen A, 32% - B, 27% - C; non-responders: 43% regimen A, 
31% - B, 27% - C). 
Responses were compared for each of the 10 outcome variables between those who responded 
close to the due date (within two weeks of T1 and T2, and six weeks of T3, T4 and T5) with those 
who responded later, but within the required time frame (numbers were too small to compare those 
that responded earlier than expected). No differences were found between these groups for any 
generic or cancer-specific HRQoL subscales except that at T1, later respondents reported higher 
care-giving burden (mean = 3.23) than early respondents (mean = 2.64, p<0.005) and at T2, later 
respondents reported less problem with nausea (mean = 0.97) than earlier respondents (mean = 
1.41, p<0.005). 
Mean scores for HRQoL subscales across time, and comparisons with norms for healthy children are 
shown in Table 2. At each time-point, Total, Physical and Psychosocial HRQoL scores were 
significantly lower than norms for healthy children. 
  
i) HRQoL change over time 
Physical, Psychosocial and Total HRQoL scales varied across time-points (F = 397.35, p < 0.0005; F = 
216.34, p < 0.0005; F = 391.37, p < 0.0005 respectively). Comparing scores at T2 to T5 against the 
preceding time-point indicated a significant decrease in generic HRQoL on each scale between T1 
and T2, followed by recovery between T2 and T3. Changes in generic HRQoL between T3, T4 and T5 
were positive and significant, though the degree and rates of change were smaller (Table 2 & Figure 
2A). 
  
Four cancer-specific HRQoL subscales, (pain and hurt, procedural anxiety, communicating about 
illness and worries about side effects) showed a significant reduction between T2 and T3 before 
levelling between T3 and T5. Nausea increased significantly between T2 and T3 and then declined to 
T5. Concern for appearance showed no significant change over time (Figure 2B). 
  
Care-giving burden was highest at T1 and T2, followed by a rapid then gradual decrease in scores 
reflecting a reduction in parental burden of care over time (Figure 2C). 
iii) Effects of age, gender and treatment on HRQoL and change over time 
There were no significant differences in generic HRQoL or care-giving burden by treatment intensity 
(regimen A, B, orC). However, there were treatment differences in cancer-specific HRQoL, . Parents 
of patients receiving regimen A reported fewer problems with pain and nausea than regimen B 
(F=7.98, p<0.05; F=9.32, p<0.005 respectively). There were no significant differences between 
regimens B or C for any HRQoL variables. Interaction effects between treatment received and time-
point were significant for just one measure: communicating effects of illness (regimen by time-point 
interaction F=6.55, p<0.05). There was a reduction in overall problems reported between T2 and T3 
but this only reached statistical significance for patients on regimen A (p<0.005) 
  
There were no significant differences in HRQoL or care-giving burden by number of DIs received. 
Interaction effects between number of DIs and time-point for generic HRQoL, cancer-specific HRQoL 
and parental burden of care were likewise non-significant. 
  
There were few gender effects, except that parents of girls consistently reported worse problems 
ǁŝƚŚ ‘ĐŽŶĐĞƌŶĨŽƌĂƉƉĞĂƌĂŶĐĞ ?ƚŚĂŶƉĂƌĞŶƚƐŽĨďŽǇƐ ?&A? ? ? ? ? ƉAM ? ? ? ? ? ? ?ĨĨĞĐƚƐŽĨŐĞnder on 
change over time (i.e. gender by time-point interaction) were only significant for nausea (F = 7.33, p 
< 0.005). There was a significant increase in nausea between T2 and T3 in boys (p<0.005) but the 
increase was smaller and non-significant in girls. Conversely nausea decreased significantly between 
T4 and T5 in girls (p<0.005) but less in boys (p=NS), . 
  
Parents of older children were more likely to report that their child worried about side-effects 
(F=113.14, p < 0.005), and had concerns about appearance (F=26.12, p < 0.005), but parents of 
younger children reported greater child procedural anxiety (F=33.29, p < 0.005) especially at T2 (age 
by time-point interaction F=8.41, p<0.005; age effect at T2 p<0.005) and lessened with time. 
  
Changes in HRQoL for patients randomised in the MRD low and high risk randomisations. 
  
MRD low-risk (n=521) were randomised between 1 and 2 DI and MRD high-risk children (n=533) 
were randomised between continuing on regimen A/B and changing to regimen C. Parents of 170 
low-risk randomised children (84 with 2 DI, 86 with 1 DI) and parents of 138 high-risk randomised 
children (64 from regimen A/B, 74 from regimen C) completed HRQoL measures at least once 
between T3 and T5. There were no statistically significant effects of randomisation on parental care-
giving burden or HRQoL , although both reduced subsample sizes and number of relevant time-
points should be considered when assessing these findings. 
  
  
  
  
DISCUSSION 
  
This is a large prospective study of HRQoL in children and adolescents undergoing treatment for ALL, 
and it provides important outcome data charting the impact on child HRQoL. Children experience 
highly compromised HRQoL from diagnosis and up to 2 years later confirming previous cross 
sectional findings [15]. This study supports previous study findings that children have a significant 
reduction in HRQoL scores across all domains [16]. One advantage of this study is the prospective 
design, which allows measurement over the whole treatment course demonstrating changes in 
HRQoL scores over time. The study also identifies important differences between younger and older 
children in their reactions. 
  
The study extends previous findings that show that children treated for ALL experience very 
compromised HRQoL immediately after diagnosis [15], but HRQoL improves from 3 W6 months and 
one year after diagnosis [17].  Parent reports of child HRQoL were much lower at T2 (4 weeks after 
diagnosis) than pre-treatment, and parental care-giving burden levels were at their highest at T1 and 
T2, confirming this initial period as one of great stress for families. 
  
Few gender differences were identified, except that parents of girls consistently reported more 
ƉƌŽďůĞŵƐǁŝƚŚ ‘ĐŽŶĐĞƌŶĨŽƌĂƉƉĞĂƌĂŶĐĞ ? ?dŚĞƐĞĐŽŶĐĞƌŶƐĂŵŽŶŐŐŝƌůƐŵĂǇďe amenable to direct 
support and intervention throughout the treatment period.   There was greater increase in nausea 
between T2 and T3 in boys, although there is no clear reason for this. 
  
Parents reported that symptoms such as nausea affected all children regardless of age but older 
children were more concerned about side effects and appearance than younger children. Parents 
reported more procedural anxiety among younger children.  
  
Parents of children receiving regimen A were less likely to report procedural pain and nausea than 
parents of those receiving regimen B. Related problems in Regimen C patients were more similar to 
regimen B. Problems with communicating effects of illness in regimen B did not change significantly 
over time whereas A and C patients had non-significantly more problems at T2 but rates dropped 
between T2 and T3 and thereafter remained similar to rates seen in regimen B. 
  
No evidence was found to support the hypothesis that one DI was associated with better HRQoL 
than two DI, either for the whole group or MRD low risk patients randomised to 1 versus 2 DI. Nor 
were hypothesised differences between MRD high-risk patients randomised to regimen A/B versus C 
evident. It is possible that the HRQoL measures were not sufficiently sensitive to detect the impact 
of the different treatment regimens or that there was too much variability round assessment time-
points, especially in the small numbers randomised in the low and high risk randomisations. 
However, results are consistent with other work suggesting that current treatments have adverse 
implications for HRQoL [18] and neurological functioning [19] and these may overwhelm more subtle 
differences related to treatment. 
  
There were a number of limitations to this study. Firstly, recruitment rates differed between centres, 
from 94% of eligible patients responding at least once to 18%. In addition, particularly at the later 
time points, there were a significant number of questionnaires that were not completed and this 
could adversely affect the validity of the results obtained. These differences may partly reflect 
availability of research staff between centres. No funding was available to support recruitment. 
Despite this, no differences in demographic or treatment were found between patients in the study 
and those not, suggesting that differential recruitment rates do not challenge the integrity of the 
findings. 
  
One limitation of this study is that assessment of HRQoL at diagnosis is a retrospective judgment and 
may therefore be unreliable.  However, the aim was to assess the impact of therapy on HRQoL and 
without this measure the baseline is entirely unknown. Many patients are unwell prior to diagnosis 
and this may result in parents under-ĞƐƚŝŵĂƚŝŶŐƚŚĞĐŚŝůĚ ?ƐƉƌĞ-illness HRQoL. 
  
The timing of recruitment around the fivedata-collection time-points was variable, especially T3 
which was affected by allocated regiment (A, B or C), treatment delays and number of DIs. T3 and T5 
were chosen to represent particular points in the treatment protocol (pre-maintenance and end-of-
treatment), rather than an absolute time-point. Variation in response time was greater than 
anticipated and needs to be addressed in design of future similar trials.  However, these data do not 
suggest that longer treatment for boys compromised their HRQoL more than girls in any measurable 
way, at least over the period of this study. 
  
The age range of children recruited to the HRQoL study was 4-18 years although the main trial 
included younger children and those up to 25 years of age. Difficulties were experienced obtaining 
responses from children especially those in the younger age-range, and no single HRQoL measure is 
sensitive across such a broad age-range. As a result, younger children were not represented even 
though they represent a significant proportion of the ALL population. This is an important limitation 
as studies have shown that there are clear differences between child self reports and parent proxy 
report, particularly in social and emotional domains. There is generally greater concordance 
between responses to questions regarding physical functioning [20]. In addition, generic HRQoL was 
compared to US population norms. These norms were chosen given the extensive validation work 
that has been reported [22], but may be sub-optimal for UK populations. The US sample differs in 
age, sex and ethnic distribution compared to the UKALL 2003 sample but given the way data were 
reported, it was impossible to allow for these differences in analysis. However, mean scores in the 
study population are so much lower than norms that these differences are unlikely to change the 
conclusions.  The measure of care-giving burden was initially developed for work involving families 
of children with asthma. Although most items were relevant and the scale was acceptable to 
parents, a more specific care-giving measure might be more sensitive such as that developed by 
Wells et al [23]. 
  
CONCLUSION 
  
This prospective study demonstrates a significant impact of therapy on HRQoL for children receiving 
treatment for ALL. Excellent survival rates mean that it is possible to reduce treatment intensity for 
some patients in an attempt to improve QoL. It is therefore vital that accurate and sensitive QoL 
measurement is undertaken. 
Further trials are needed to confirm these findings from the perspective of the patient and to 
determine whether HRQoL can be enhanced by clinical or supportive interventions for patients and 
their families   A fuller understanding of the impact of therapy on HRQoL in patients with ALL will 
make an important contribution to the development of patient reported outcomes among young 
people. 
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LEGENDS 
Figure 1: Flow chart of eligibility and response in the UKALL2003 QOL trial 
  
Figure 2: (A) Mean child generic (Total, Physical and Psychosocial) HRQoL by time (higher scores = 
higher functioning/QOL. (B) Mean cancer-specific HRQoL subscale scores by time (higher scores = 
ŵŽƌĞƉƌŽďůĞŵƐ ? ? ?DĞĂŶWĂƌĞŶƚ ?ƐĂƌĞ-Giving Burden by time (higher score = higher burden) 
  
  
  
  
 
